Updates are available Correction dated 2025-11-03
Click to view Correction: https://doi.org/10.1038/s41375-025-02793-2
Updates are available Correction dated 2025-12-02
Click to view Correction: https://doi.org/10.1038/s41375-025-02824-y
-
Authors
Tedeschi, Alessandra
Frustaci, Anna Maria
Menna, Pierantonio https://orcid.org/0000-0002-7755-818X
Minotti, Giorgio https://orcid.org/0000-0002-5678-6175
- License Information
-
More Information
Article History
Received: 5 July 2025
Revised: 7 September 2025
Accepted: 19 September 2025
First Online: 2 October 2025
Change Date: 2 December 2025
Change Type: Update
Change Details: The original online version of this article was revised: In the sentence beginning ‘On the other hand, the data are quite...’ in this article, the text ‘over venetoclax’ should have read ‘over acalabrutinib’. The original article has been corrected.
Change Date: 2 December 2025
Change Type: Correction
Change Details: A Correction to this paper has been published:
Change Details: https://doi.org/10.1038/s41375-025-02824-y
Change Date: 3 November 2025
Change Type: Correction
Change Details: A Correction to this paper has been published:
Change Details: https://doi.org/10.1038/s41375-025-02793-2
Competing interests
: AT has received honoraria for participation in advisory boards from AbbVie, AstraZeneca, BeiGene, Johnson & Johnson, Lilly, and is a participant in speaker bureaus for AbbVie, BeiGene, and Johnson & Johnson. AMF has received honoraria for participation in advisory boards and has received sponsorships for congresses from AbbVie, AstraZeneca, BeiGene, Johnson & Johnson. PM is a participant in speaker bureaus for Johnson & Johnson. GM has received honoraria for participation in advisory boards from BeiGene, Incyte, Johnson & Johnson, Lilly, and Servier, and is a participant in speaker bureaus for AbbVie, BeiGene, and Johnson & Johnson.
